受体酪氨酸激酶RON在上皮源性肿瘤靶向治疗中的研究进展  

Research Progress of RON Receptor Tyrosine Kinase in the Targeted Therapy of Epithelial Tumor

作　　者：余晓雯[1] 赵文权[2] 吴连俊[1] 王慧明[1,2] 

机构地区：[1]浙江大学医学院附属口腔医院,浙江杭州310006 [2]浙江大学医学院附属第一医院,浙江杭州310003

出　　处：《中国肿瘤》2016年第9期711-714,共4页China Cancer

基　　金：浙江省医药卫生科技项目(2015103983)

摘　　要：RON(recepteur d’origine nantais)属于受体酪氨酸激酶(receptor tyrosine kinases,RTKs)原癌基因家族中c-Met亚家族的一员,其配体是巨噬细胞刺激蛋白(macrophage stimulating protein,MSP)。受体酪氨酸激酶RON过度表达、变异体的产生以及点突变,将激活RON信号通路,从而促进癌细胞增殖、侵袭,有利于血管生长以及提高细胞耐药性。大量研究表明,RON及其变异体与人体某些上皮源性肿瘤的发生和发展有密切关系。全文重点综述RON在恶性肿瘤发生发展中的作用机制以及在上皮源性肿瘤靶向治疗中的潜在可能性。Recepteur d＇origine nantais（RON） is a member of the c-Met subfamily of receptor tyro- sine kinases （RTK） proto-oncogene family. Macrophage stimulating protein （MSP） is the ligand of RON. The over expression of the RON,and point mutation as well as the variants production will activate the RON signaling pathway,which promotes cell proliferation,infiltration,drug-resistance and induces angiogenesis in tumor. Many studies have indicated that RON and its variants were related to the occurrence and development of some epithelial tumors of human closely. The aims of the study were to clarify the mechanism of RON in the development of malignant tumor and to ex- plore the RON-targeted therapy to epithelial tumor.

关 键 词：受体酪氨酸激酶RON 上皮源性肿瘤 作用机制 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]